AbbVie CEO Rob Michael (L) and Gubra CEO Henrik Blou
March 3, 2025 03:56 AM ESTUpdated 07:06 AM
Deals
Pharma

Ab­b­Vie fi­nal­ly en­ters obe­si­ty race with $350M up­front for Gubra’s amylin

Kyle LaHucik

Senior Reporter

One of the last big phar­ma hold­outs in obe­si­ty has now en­tered what has be­come the most sought-af­ter field in the in­dus­try.

Ab­b­Vie said Mon­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Trump’s broad tar­iffs ex­empt phar­ma — but for how long?

PIPEs, bio­phar­ma’s fa­vorite fi­nanc­ing ve­hi­cle, freeze amid mar­ket strug­gles

Chaot­ic tar­iff roll­out leaves as many ques­tions as an­swers for drug­mak­ers

An­oth­er TIG­IT tri­al fails as BeiGene scraps Phase 3 drug

Sarep­ta, Roche pause Ele­v­idys tri­als in Eu­rope fol­low­ing pa­tient death

sponsored

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

A service from the Financial Times